Novartis Ag (NYSE: NVS)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Novartis Ag Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Novartis Ag Company Info
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
News & Analysis
Commercial real estate stocks offer opportunities to get involved with some of the most interesting businesses in the world.
The Swiss pharmaceutical giant possesses a tremendous product pipeline.
These two pharma stocks are rock-solid picks in any kind of market.
One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry.
These CRISPR stocks could be big winners for patient investors.
This big pharma company pays a market-topping dividend to shareholders.
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.
You're getting a lot of bang for your buck with these stocks.
We examine three biotech companies' past performances and future outlooks.
Here’s how CAR-T therapies did in their first full year on the market.
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
The 21st Century Cures Act ignites innovation with perks to biopharma and medical device makers. Also, Kite Pharma and Novartis prep plans to pitch their CAR-T cancer therapies to the FDA.
NVS earnings call for the period ending December 31, 2022.
NVS earnings call for the period ending September 30, 2022.
NVS earnings call for the period ending June 30, 2022.
NVS earnings call for the period ending March 31, 2022.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.